Biocon gets EIR with VAI status from USFDA for Bengaluru API facility

09 Dec 2024 Evaluate

Biocon has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (USFDA), for its API facility (Site 2), located at SEZ Plot no. 2,3,4 and 5 Bommasandra-Jigani Link Road, Bengaluru, Karnataka. This is based on a surveillance inspection conducted by the agency between September 23 to 27, 2024. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

380.60 2.80 (0.74%)
16-Feb-2026 14:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1699.95
Dr. Reddys Lab 1269.00
Cipla 1352.20
Zydus Lifesciences 909.95
Lupin 2221.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×